AbbVie Inc (ABBV)vsFortrea Holdings Inc. (FTRE)
ABBV
AbbVie Inc
$263.65
+0.04%
HEALTHCARE · Cap: $447.53B
FTRE
Fortrea Holdings Inc.
$20.40
-1.45%
HEALTHCARE · Cap: $1.69B
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 2219% more annual revenue ($62.82B vs $2.71B). ABBV leads profitability with a 5.8% profit margin vs -16.5%. FTRE appears more attractively valued with a PEG of 0.34. ABBV earns a higher WallStSmart Score of 63/100 (C+).
ABBV
Buy63
out of 100
Grade: C+
FTRE
Hold40
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-78.8%
Fair Value
$147.26
Current Price
$263.65
$116.39 premium
Margin of Safety
-39.5%
Fair Value
$8.31
Current Price
$20.40
$12.09 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Growing faster than its price suggests
Every $100 of equity generates 62 in profit
Strong operational efficiency at 32.2%
Conservative balance sheet, low leverage
Generating 3.6B in free cash flow
Growing faster than its price suggests
Areas to Watch
5.8% margin — thin
Premium valuation, high expectations priced in
Earnings declined 46.2%
Distress zone — elevated risk
Smaller company, higher risk/reward
Operating margin of 0.5%
Weak financial health signals
ROE of -85.0% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, PEG Ratio, Return on Equity. Revenue growth of 12.4% demonstrates continued momentum. PEG of 0.42 suggests the stock is reasonably priced for its growth.
Bull Case : FTRE
The strongest argument for FTRE centers on PEG Ratio. PEG of 0.34 suggests the stock is reasonably priced for its growth.
Bear Case : ABBV
The primary concerns for ABBV are Profit Margin, P/E Ratio, EPS Growth. A P/E of 124.8x leaves little room for execution misses.
Bear Case : FTRE
The primary concerns for FTRE are Market Cap, Operating Margin, Piotroski F-Score. Debt-to-equity of 2.13 is elevated, increasing financial risk.
Key Dynamics to Monitor
ABBV profiles as a value stock while FTRE is a turnaround play — different risk/reward profiles.
FTRE carries more volatility with a beta of 2.01 — expect wider price swings.
ABBV is growing revenue faster at 12.4% — sustainability is the question.
ABBV generates stronger free cash flow (3.6B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (63/100 vs 40/100) and 12.4% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
Fortrea Holdings Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Fortrea Holdings Inc. provides clinical development and patient access solutions to the life sciences industry. The company is headquartered in Durham, North Carolina.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?